Insider · CIK 0001731193
Nadim Ahmed
Files at CGEM (Cullinan Therapeutics, Inc.), IRON (Disc Medicine, Inc.). First filing Dec 27, 2024, latest Feb 25, 2026.
In brief
Nadim Ahmed files SEC Form 4 as CEO, president and director at CGEM (Cullinan Therapeutics, Inc.), and also at IRON (Disc Medicine, Inc.). Since Dec 27, 2024, Nadim Ahmed has reported 0 open-market buys worth $0 and 5 open-market sells worth $725k, the latest filed on Feb 25, 2026.
A track record needs three past buys with six months of prices behind them; Nadim Ahmed has 0, so none is measured yet.
The newest scored trade: sold $196k of CGEM on Feb 24, 2026, filed Feb 25, 2026, scored 52 (moderate). In the last 12 months: 0 buys worth $0 and 3 sells worth $518k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CGEM: Cullinan Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 52Moderate | Cullinan Therapeutics, Inc. | $196k 13,515 shares | -3% | +148% from low0% from high | |
| 52Moderate | Cullinan Therapeutics, Inc. | $223k 16,381 shares | -4% | +137% from low-2% from high | |
| 50Moderate | Cullinan Therapeutics, Inc. | $99k 9,922 shares | -2% | +74% from low-23% from high | |
| 50Moderate | Cullinan Therapeutics, Inc. | $107k 12,529 shares | -3% | 0% from low-53% from high | |
| 50Moderate | Cullinan Therapeutics, Inc. | $100k 8,400 shares | -3% | +14% from low-32% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | IRON Disc Medicine, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,176 | $0.00 | $0 | 5,176 | Jun 23, 2026 |
| Feb 24, 2026 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -13,515 | $14.47 | $196k | 390,803 | Feb 25, 2026 |
| Feb 20, 2026 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -16,381 | $13.62 | $223k | 404,318 | Feb 23, 2026 |
| Feb 18, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +828,000 | $0.00 | $0 | 828,000 | Feb 19, 2026 |
| Dec 23, 2025 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -9,922 | $10.01 | $99k | 420,699 | Dec 29, 2025 |
| Jul 14, 2025 | IRON Disc Medicine, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jul 16, 2025 |
| Feb 25, 2025 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -12,529 | $8.53 | $107k | 430,621 | Feb 27, 2025 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +180,000 | $0.00 | $0 | 443,150 | Feb 21, 2025 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +360,000 | $0.00 | $0 | 360,000 | Feb 21, 2025 |
| Dec 24, 2024 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -8,400 | $11.87 | $100k | 263,150 | Dec 27, 2024 |
Questions about Nadim Ahmed
Answered from the filings on this page, as of the latest one.
Is Nadim Ahmed buying or selling?
In the last 12 months Nadim Ahmed reported 0 open-market buys worth $0 and 3 open-market sells worth $518k on SEC Form 4; the latest was sold $196k of CGEM on Feb 24, 2026. Grants, option exercises and tax withholding are not counted.
How did Nadim Ahmed's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nadim Ahmed has 0.
Where does Nadim Ahmed file Form 4?
Nadim Ahmed has filed Form 4 at CGEM (Cullinan Therapeutics, Inc.) as President and CEO; IRON (Disc Medicine, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.